New schizophrenia injection compared to market leader in chinese trial
NCT ID NCT07493551
First seen Apr 02, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This study compares a new version of the long-acting schizophrenia injection paliperidone palmitate (given every 3 months) to the approved drug Invega Trinza. About 260 adults with stable schizophrenia will receive multiple doses to see if the new formulation works similarly in the body. The goal is to confirm bioequivalence, meaning the new injection is expected to control symptoms just as well as the existing one.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anding Hospital Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100120, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.